Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,299 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Pediatric Clear all
Active, not recruiting Not applicable Interventional

Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors

NCT05665543
View directory record Official record
Conditions
Cancer, HPV Associated Cancer
Interventions
GLAm app
Behavioral
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
9 Years to 26 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Recruiting No phase listed Observational

Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy

NCT05440617
View directory record Official record
Conditions
Acute Ovarian Failure, Infertility, Early Menopause And Infertility In Females After Treatment For Childhood Cancer
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
4 Years to 35 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2041
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 1 Interventional Results available

Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma

NCT03615404
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme, Pediatric Brain Tumor, Recurrent, Pediatric Brain Tumor
Interventions
CMV-DCs with GM-CSF, Td (tetanus toxoid)
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
0 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 20, 2026, 7:41 AM EDT
Active, not recruiting No phase listed Observational

Remote Exercise Video Adaptations to Maximize Physical Activity in Childhood Cancer

NCT06411704
View directory record Official record
Conditions
Frailty, Survivorship, Childhood Cancer
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 39 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Active, not recruiting Phase 2 Interventional

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

NCT03755804
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
bendamustine, Etoposide, Doxorubicin, Bleomycin, Vincristine, Vinblastine, Prednisone, Filgrastim, Brentuximab Vedotin, Cyclophosphamide, DTIC, Quality of Life Measurements, Radiotherapy
Drug · Other · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
8
States / cities
Palo Alto, California • Peoria, Illinois • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Completed No phase listed Observational

Preventing Cardiac Sequelae in Pediatric Cancer Survivors

NCT01805778
View directory record Official record
Conditions
Anthracycline-induced Cardiotoxicity
Interventions
Not listed
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
Up to 18 Years
Enrollment
1,128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional

Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment

NCT04400071
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Pediatric Cancer
Interventions
Active Music Engagement, Audio Storybooks
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
3 Years to 8 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Oakland, California • Chicago, Illinois • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Financial and Insurance Assistance- Oncology Financial and Legal Navigation Program

NCT05876325
View directory record Official record
Conditions
Financial Stress, Pediatric Cancer
Interventions
FINassist Patient, FINassist Caregiver
Other
Lead sponsor
Jean Edward
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

NCT01036009
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia, Pre-leukemic Syndromes, Monosomy 7, Bone Marrow Clonal Malformations, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
Interventions
Withdrawal of immunosuppression and donor lymphocyte infusion
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 25 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
San Francisco, California • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Oct 20, 2026, 7:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

NCT06303193
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
pacritinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

NCT03792633
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
huCART19
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
3 Months to 29 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 4 Interventional

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

NCT00230217
View directory record Official record
Conditions
Tumors, Hyperuricemia, Tumor Lysis Syndrome
Interventions
Rasburicase (SR29142)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Berkley, California • Denver, Colorado • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2009 · Synced Oct 20, 2026, 7:41 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT07306832
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Pivekimab Sunirine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Months to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Atlanta, Georgia • Valhalla, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Completed No phase listed Observational

Brain Imaging Changes Following Proton Therapy for Pediatric Primary Central Nervous System and Base of Skull Tumors

NCT04296617
View directory record Official record
Conditions
Malignant Central Nervous System Neoplasm, Malignant Skull Base Neoplasm
Interventions
Medical Chart Review
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 20, 2026, 7:41 AM EDT
Recruiting Phase 1 Interventional

Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma

NCT07061626
View directory record Official record
Conditions
Ependymoma, High Grade Gliomas
Interventions
Rhenium-186 Nanoliposome
Drug
Lead sponsor
Cerenome
Industry
Eligibility
6 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

NCT05322850
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis), Chronic Myeloid Leukemia - Accelerated Phase
Interventions
Orca-Q
Biological
Lead sponsor
University of Florida
Other
Eligibility
Up to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Gainesville, Florida • Miami, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Withdrawn Phase 1 Interventional

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

NCT00886496
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
recombinant human mannose-binding lectin
Biological
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Orange, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 20, 2026, 7:41 AM EDT
Active, not recruiting Phase 1 Interventional

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

NCT07492316
View directory record Official record
Conditions
Recurrent Medulloblastoma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 39 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

NCT00777036
View directory record Official record
Conditions
Leukemia
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Day to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobile-based Social Services Screening and Referral Tool in an Pediatric Emergency Department

NCT03562910
View directory record Official record
Conditions
Poverty, Social Determinants of Health, Mobile Applications, Pediatric ALL, Emergencies
Interventions
HelpSteps application
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 20, 2026, 7:41 AM EDT
Completed No phase listed Observational

Genetic Study of Families With High Frequency of Hodgkin Lymphoma

NCT02795013
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas

NCT01188096
View directory record Official record
Conditions
Brain Tumors
Interventions
Poly ICLC
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
San Diego, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Phase 1 Interventional Results available

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

NCT03323034
View directory record Official record
Conditions
Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm
Interventions
Irinotecan, Pevonedistat, Temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 20, 2026, 7:41 AM EDT
Completed Not applicable Interventional

Exercise and Pain in CCS

NCT05562193
View directory record Official record
Conditions
Childhood Cancer Survivors
Interventions
Physical activity intervention coupled with standard post-cancer directed treatment care, Standard post-cancer directed treatment care control
Behavioral · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
10 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 20, 2026, 7:41 AM EDT